{"filings":[{"id":95713,"accession_number":"0001193125-26-205187","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine Q1 net loss widens to $63.5M; bitopertin Phase 3 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.5M vs $34.1M YoY; R&D expenses rose to $45.9M, SG&A to $23.6M.","Cash and securities $730.2M at March 31, 2026, funding operations into 2029.","Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (N=183); topline data Q4 2026.","Updated Phase 2 DISC-0974 (MF anemia) data to be presented at ASCO June 2026 (N=61).","Phase 2 DISC-3405 (PV) and Phase 1b (SCD) data both expected in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108983,"accession_number":"0001193125-26-082855","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Disc Medicine cuts 20% of workforce after FDA complete response letter for bitopertin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restructuring plan approved Feb 26, 2026, reducing workforce by ~20%.","FDA issued complete response letter Feb 13, 2026 for bitopertin NDA in erythropoietic protoporphyria and X-linked protoporphyria.","Expected aggregate charges of ~$2.0 million, primarily severance, recorded in Q1 2026.","Implementation expected to be completed in Q2 2026; reductions focused on commercial and support functions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108982,"accession_number":"0001193125-26-073594","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine reports FY2025 net loss $212.2M; receives CRL for bitopertin; cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $212.2M for FY2025, up from $109.4M in FY2024; driven by higher R&D and SG&A costs.","Cash, cash equivalents and marketable securities of $791.2M as of Dec 31, 2025, up from $489.9M.","FDA issued Complete Response Letter for bitopertin in EPP in Feb 2026; Phase 3 APOLLO topline data expected Q4 2026.","Phase 2 data for DISC-0974 in MF anemia showed durable hemoglobin benefits across subgroups at ASH.","DISC-3405 Phase 2 in PV and Phase 1b in SCD ongoing; initial data expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108981,"accession_number":"0001193125-26-053066","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Disc Medicine's bitopertin NDA in erythropoietic protoporphyria","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued a Complete Response Letter on February 13, 2026 for bitopertin NDA for erythropoietic protoporphyria (EPP).","The CRL indicates FDA will not approve the NDA in its current form, typically requiring additional data or analyses.","Disc Medicine hosted a conference call on February 17, 2026 to discuss the CRL and next steps; webcast available for 30 days.","Bitopertin is Disc Medicine's lead product candidate; this regulatory setback materially impacts the company's pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108980,"accession_number":"0001193125-26-051504","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Disc Medicine's bitopertin NDA for EPP; approval delayed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA acknowledged bitopertin significantly lowers PPIX but found insufficient evidence that PPIX change predicts clinical benefit.","Phase 3 APOLLO study ongoing; topline data expected Q4 2026; could support traditional approval.","Company plans Type A meeting with FDA; expects resubmission and decision by mid-2027 if APOLLO successful.","Disc Medicine has approximately $791M cash (unaudited, Dec 31, 2025) with runway into 2029.","CRL delays potential approval; stock likely to face negative pressure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108979,"accession_number":"0001193125-26-009871","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Disc Medicine reports $791M cash; bitopertin NDA under priority review with CNPV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents and securities ~$791M as of Dec 31, 2025; runway into 2029.","Bitopertin NDA for EPP accepted under accelerated approval; CNPV expected to accelerate FDA review to 1-2 months.","Key 2026 milestones: updated Phase 2 data for DISC-0974 (MF anemia) and DISC-3405 (PV/SCD) in H2.","Preparation for US launch of bitopertin if approved; commercial team and infrastructure build-out completed.","Phase 2 study of DISC-0974 in anemia and inflammatory bowel disease to be initiated in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125439,"accession_number":"0001193125-25-310664","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Disc Medicine holds Dec 7 call to review ASH 2025 data and operational plans; exhibit incomplete","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Conference call held on December 7, 2025 to review data from 67th ASH Annual Meeting.","Operational plans were also discussed; slide presentation attached as Exhibit 99.1.","No financial results, guidance, or specific data disclosed in the 8-K filing body.","Exhibit 99.1 is a slide deck; its content was not fully provided to analyst.","Company undertakes no obligation to update or supplement the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125438,"accession_number":"0001193125-25-268196","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine reports Q3 net loss of $62.3M; files NDA for bitopertin in EPP with priority review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Submitted NDA for bitopertin in EPP seeking accelerated approval; FDA CNPV shortens review to 1-2 months; potential US launch late 2025/early 2026.","Cash and equivalents $615.9M as of Sep 30; Oct public offering added ~$211M net; cash runway extended into 2029.","R&D expenses $50.3M (up from $24.7M) driven by pipeline progression, including $10M milestone for DISC-3405.","Net loss widened to $62.3M from $26.6M in Q3 2024 due to higher operating costs for clinical programs and commercial prep.","Initial Phase 2 data for DISC-0974 in myelofibrosis anemia to be presented at ASH December 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125437,"accession_number":"0001193125-25-245871","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine prices upsized $250M offering; net proceeds ~$210.9M to fund bitopertin and extend cash runway into 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds to Disc Medicine expected ~$210.9M; funds will support bitopertin commercialization for EPP/XLP, R&D, and general corporate purposes.","Selling stockholder AI DMI LLC sold 297,619 shares at $84.00; underwriters exercised option to purchase additional 446,428 shares from AI DMI.","Company expects cash, equivalents, and marketable securities plus offering net proceeds to fund operations into 2029, excluding potential bitopertin revenue.","Pre-funded warrants have $0.0001 exercise price, immediate exercisability, and 24.99% ownership limit; not listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125436,"accession_number":"0001193125-25-242959","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine reports $615.9M cash; bitopertin NDA submitted for accelerated review (CNPV)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents and marketable securities of ~$615.9M as of September 30, 2025.","NDA for bitopertin in EPP submitted Sept 29, 2025; awarded FDA CNPV for 1-2 month review; potential US approval late 2025/early 2026.","Phase 2 RALLY-MF trial of DISC-0974 in anemia of MF: initial data by year-end 2025, topline data in 2026.","DISC-3405 Phase 2 PV topline data expected 2026; Phase 1b in sickle cell disease by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125435,"accession_number":"0001193125-25-242026","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Disc Medicine receives FDA priority voucher for bitopertin in EPP; review time cut to 1-2 months","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted CNPV for bitopertin in erythropoietic protoporphyria (EPP) including X-linked protoporphyria.","NDA submitted September 2025 under accelerated approval pathway for patients aged 12+.","CNPV program reduces standard FDA review to 1-2 months; includes rolling review and enhanced communications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125434,"accession_number":"0001193125-25-231911","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Disc Medicine director Mona Ashiya resigns; board reduced to eight members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mona Ashiya, Ph.D., resigned as Class I director effective October 3, 2025.","She also left the Compensation and Nominating/Corporate Governance Committees.","Resignation was not due to any disagreement with the Company.","Board size decreased from nine to eight members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142170,"accession_number":"0001816736-25-000006","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine Q2 net loss $55.2M; on track for bitopertin NDA in October 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $650.0M as of June 30, 2025; expected to fund operations into 2028.","NDA submission for bitopertin in EPP under accelerated approval planned for October 2025 after positive pre-NDA meeting.","Phase 2 data from DISC-0974 in MF anemia and multiple-dose data from Phase 1b in NDD-CKD anemia expected Q4 2025.","Initiated Phase 2 study of DISC-3405 in polycythemia vera; initial data anticipated in 2026.","Appointed Nadim Ahmed (Cullinan Therapeutics CEO) to Board of Directors in July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142169,"accession_number":"0000950170-25-095466","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Disc Medicine elects Nadim Ahmed as Class I director effective July 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nadim Ahmed elected to Board as Class I director, term until 2027 annual meeting.","Ahmed receives $40,000 annual cash retainer and a 20,000-share option vesting over three years.","Ahmed enters into standard indemnification agreement with the Company.","No arrangements or material transactions with other persons disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160165,"accession_number":"0000950170-25-086352","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Disc Medicine stockholders elect three Class II directors, approve say-on-pay, ratify EY auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Georges Gemayel, Mark Chin, and Liam Ratcliffe as Class II directors for three-year term ending 2028.","Non-binding advisory vote approved executive compensation: 30,801,342 for, 235,453 against, 6,286 abstain.","Stockholders recommended say-on-pay vote every year; board adopted annual frequency until at least 2031.","Ratified Ernst & Young as independent registered public accounting firm for FY2025: 32,117,099 for, 2,370 against, 488 withheld.","All proposals passed with majority support; broker non-votes ranged from 1,076,876 on director elections to none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160164,"accession_number":"0000950170-25-065031","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine Q1 net loss $34.1M, cash $694.7M; bitopertin NDA on track H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended Q1 with $694.7M cash; expects to fund operations into 2028 after $259M January offering.","Net loss $34.1M vs $26.9M YoY; R&D expense $27.8M, SG&A $12.2M, both up on pipeline progress.","Bitopertin NDA in erythropoietic protoporphyria (EPP) planned for H2 2025; APOLLO confirmatory trial initiated.","DISC-3405 Phase 2 in polycythemia vera expected to start H1 2025; initial DISC-0974 data due H2 2025.","Successful CMC-focused end-of-Phase-2 meeting with FDA; drug substance and product manufactured in US."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178479,"accession_number":"0001193125-25-037650","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine: 2024 net loss $109.4M, bitopertin NDA on track H2 2025 via accelerated approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 net loss $109.4M vs $76.4M in 2023; R&D expenses rose to $96.7M.","Cash $489.9M at year-end; plus $243.3M net from Jan 2025 offering, funds operations into 2028.","Bitopertin: FDA path to accelerated approval for EPP; NDA submission planned H2 2025.","DISC-0974: Phase 2 MF anemia trial initiated; initial data expected H2 2025.","DISC-3405: Phase 2 in polycythemia vera expected H1 2025; Phase 1 showed proof-of-mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178478,"accession_number":"0001193125-25-012211","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine prices $225.5M upsized public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 3,918,182 shares at $55.00/share and 181,818 pre-funded warrants at $54.9999 each.","Gross proceeds ~$225.5M; net proceeds ~$243.3M after underwriters' option exercised in full.","Proceeds to fund clinical development, potential commercialization of bitopertin for EPP and XLP, and working capital.","Cash, equivalents, and marketable securities plus offering net proceeds expected to fund operations into 2028.","Offering closed January 24, 2025; underwriters include Jefferies, Leerink, Stifel, Cantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178477,"accession_number":"0001193125-25-009095","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine aligns with FDA on bitopertin confirmatory trial design; NDA planned H2 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Achieved FDA alignment on APOLLO post-marketing trial design for bitopertin in EPP and XLP.","Co-primary endpoints: monthly total sunlight time without pain and percent change in whole-blood PPIX.","Plans to submit NDA for accelerated approval in H2 2025 based on Phase 2 BEACON and AURORA data.","APOLLO trial to enroll ~150 patients aged 12+, randomized 1:1, 60 mg dose, double-blind placebo-controlled.","Trial initiation expected by mid-2025; enrollment underway by potential accelerated approval date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178476,"accession_number":"0000950170-25-003859","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine discloses ITGC material weakness; outlines bitopertin NDA plan and 2025 milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Material weakness in ITGC over key financial IT systems; no misstatements identified to date.","Bitopertin NDA submission plans to be discussed after Type C FDA meeting in Q1 2025; potential accelerated approval for EPP.","Initial phase 2 data for DISC-0974 in myelofibrosis anemia expected H2 2025; multiple-dose CKD data also H2 2025.","Phase 2 trial of DISC-3405 in polycythemia vera planned to start H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195154,"accession_number":"0000950170-24-134349","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Disc Medicine reviews ASH 2024 clinical data for bitopertin, DISC-0974, DISC-3405","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held conference call on Dec 8 to review data presented at ASH Annual Meeting.","Operational plans discussed alongside clinical updates for three pipeline programs.","Specific data results or guidance not provided in the 8-K filing; only presentation referenced.","Programs include bitopertin, DISC-0974, and DISC-3405."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195153,"accession_number":"0001193125-24-259855","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Disc Medicine enters $200M ATM equity sales agreement with Cantor, terminates prior Jefferies facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $200M of common stock may be sold at-the-market through Cantor Fitzgerald under a new Controlled Equity Offering agreement.","Cantor receives up to 3.0% commission on gross proceeds; sales are discretionary and subject to company instructions.","Prior Jefferies ATM agreement terminated on Nov 15, 2024; $22.5M gross proceeds from 376,363 shares sold thereunder.","No termination penalties apply; new ATM is under existing S-3 shelf registration statement (No. 333-281359)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195152,"accession_number":"0001193125-24-255200","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed successful end-of-Phase 2 meeting with FDA for bitopertin in EPP, reaching alignment on all proposed study parameters with potential for accelerated approval.","Presented proof-of-mechanism data for Phase 1b trial of DISC-0974 in NDD-CKD patients with anemia at ASN Kidney Week 2024.","Ended Q3 2024 with $487M cash; closed $200M non-dilutive debt financing with Hercules Capital in November 2024.","Net loss was $26.6M for Q3 2024, compared to $14.1M for same period in 2023.","Appointed Steve Caffé as Chief Regulatory Officer and Rahul Kaushik as Chief Technical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195151,"accession_number":"0000950170-24-123718","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Disc Medicine secures up to $200M non-dilutive debt facility from Hercules Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$200M senior secured term loan facility from Hercules Capital; $30M drawn at closing.","Up to $80M additional available at Disc's sole discretion through second-half 2026.","Remaining $90M subject to milestone achievement or lender consent.","Interest-only for at least 48 months, extendable to 60 months; matures November 2029.","Proceeds to support bitopertin EPP confirmatory trial, DISC-0974 MF/NDD-CKD studies, and DISC-3405 PV trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195150,"accession_number":"0000950170-24-120292","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine gets FDA alignment on Phase 3 plan for bitopertin in EPP; accelerated approval possible","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on all APOLLO trial parameters: single placebo-controlled study, 60 mg dose, 6-month duration, primary endpoint of monthly sunlight time without pain.","Potential for accelerated approval using PPIX reduction as surrogate endpoint, allowing NDA submission based on existing data.","APOLLO trial to include EPP and XLP patients aged 12+; initiation planned by mid-2025.","Company to meet FDA to finalize details; update on NDA timing expected Q1 2025.","Positive FDA feedback provides clear registration path for bitopertin in erythropoietic protoporphyria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195149,"accession_number":"0000950170-24-117318","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine presents positive Phase 1b data for DISC-0974 in CKD anemia at ASN Kidney Week","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dose-dependent hepcidin reduction >75% from baseline at highest dose (60 mg); transferrin saturation up to 3x baseline.","Mean hemoglobin increase of +0.55 g/dL at 60 mg vs +0.21 g/dL placebo; individual max increase +1.8 g/dL.","All treatment-related adverse events Grade 1 or 2; majority unrelated to DISC-0974; acceptable safety profile.","Data from SAD cohorts (28, 40, 60 mg) in Stage 2-5 NDD-CKD anemia; dose escalation and multiple-dose portion ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211420,"accession_number":"0001193125-24-196507","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine Q2 net loss $26.4M; cash $500.9M; positive EHA data across pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.4M for Q2 2024 vs $15.9M in Q2 2023; R&D expenses rose to $23.5M.","Cash, cash equivalents & marketable securities of $500.9M as of June 30, 2024; raised $178M in June offering.","Presented positive data for bitopertin (EPP), DISC-0974 (anemia of MF), and DISC-3405 (hepcidin) at EHA 2024.","Expects regulatory interactions for bitopertin and DISC-0974 in H2 2024; DISC-3405 MAD data also expected in H2.","Cash runway expected to fund operations well into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230054,"accession_number":"0001193125-24-161603","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Disc Medicine stockholders elect Ashiya and Bitterman as Class I directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mona Ashiya, Ph.D. received 21,799,456 votes for and 149,253 withheld.","Kevin Bitterman, Ph.D. received 16,982,922 votes for and 4,965,787 withheld.","Ratification of Ernst & Young as independent auditor for FY 2024: 22,832,763 for, 1,152 against, 551 abstain.","No other matters were voted on at the June 12, 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230053,"accession_number":"0001193125-24-161587","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine prices $178M underwritten offering of 4.94M shares at $36.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 4,944,000 shares at $36.00; gross proceeds ~$178M, net ~$172.3M.","Offering led by Frazier Life Sciences and Logos Capital with other institutional investors.","Net proceeds to fund clinical development, R&D, and working capital; cash runway extended into 2027.","Expected to close June 17, 2024; Leerink Partners acts as sole bookrunner.","Offered under effective shelf registration statement (Form S-3, No. 333-275652)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230052,"accession_number":"0001193125-24-161170","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine reports positive Phase 2 data for bitopertin in EPP and updates for DISC-0974 and DISC-3405 at EHA 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bitopertin reduced protoporphyrin IX by 40% in 60 mg group and cut phototoxic reactions by 75.3% (p=0.011) in AURORA trial.","DISC-0974 showed 68.9% of non-transfusion dependent myelofibrosis patients had hemoglobin response ≥1.5 g/dL; one TD patient became transfusion independent.","DISC-3405 demonstrated >50% mean serum iron reduction sustained for at least 4 weeks at 300 mg dose in healthy volunteers.","No serious adverse events reported across all three programs to date.","Data were presented at European Hematology Association 2024 Congress on June 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230051,"accession_number":"0001193125-24-134796","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine Q1 net loss $26.9M; bitopertin AURORA trial misses primary endpoint, but shows secondary benefits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $342.6M at March 31, 2024; provides runway well into 2026.","Net loss $26.9M in Q1 2024 vs. $22.8M in Q1 2023; R&D expense rose to $23.7M from $20.2M.","Bitopertin AURORA phase 2 in EPP: significant PPIX reduction; missed primary endpoint (light tolerance) due to placebo benefit; 60mg dose showed significant reduction in phototoxic pain reactions.","Received FDA Rare Pediatric Disease Designation for bitopertin in EPP in May 2024.","On track to present additional AURORA/BEACON data, initial DISC-3405 SAD data, and updated DISC-0974 MF data in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230050,"accession_number":"0001193125-24-084937","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Disc Medicine bitopertin Phase 2 in EPP meets primary endpoint; key secondary misses significance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: PPIX reduced 21.6% (20mg, p=0.003) and 40.7% (60mg, p<0.001) vs placebo +8.0%.","Key secondary (cumulative sunlight time) not significant: 175.1h (20mg), 153.1h (60mg) vs 133.9h placebo due to strong placebo response.","Phototoxic reactions with pain reduced 75% for 60mg (p=0.011) and 60% for 20mg (p=0.109).","Patient Global Impression of Change: 86% of 60mg completers rated 'much better' vs 50% placebo (p=0.022).","Bitopertin well tolerated, no SAEs; dizziness most common AE; two discontinuations at 60mg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248493,"accession_number":"0001193125-24-073324","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Disc Medicine reports FY2023 net loss $76.4M, cash $360.4M; AURORA topline data expected March/April 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $360.4M at Dec 31, 2023, providing runway well into 2026.","Net loss of $76.4M for FY2023 vs $46.8M in 2022, driven by higher R&D costs ($69.3M vs $33.4M).","Topline results from AURORA phase 2 study of bitopertin in EPP expected March/April 2024.","Updated phase 1b/2 data for DISC-0974 in anemia of myelofibrosis expected 1H 2024.","Appointed Jean Franchi as CFO, Pamela Stephenson as CCO, promoted Jonathan Yu to COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248492,"accession_number":"0001193125-24-045464","cik":1816736,"company_name":"Disc Medicine, Inc.","ticker":"IRON","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Disc Medicine appoints Pamela Stephenson as CCO; grants inducement equity award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pamela Stephenson, MPH, named Chief Commercial Officer effective Feb 26, 2024.","Stephenson has 25+ years biopharma experience, most recently CCO of Albireo (acquired by Ipsen).","Inducement award: option to purchase 55,000 shares and RSU for 36,666 shares under Nasdaq Rule 5635(c)(4).","Option vests 25% on first anniversary, then monthly; RSU vests in four equal annual installments.","Company is clinical-stage biopharma focused on serious hematologic diseases (NASDAQ:IRON)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2692080883.5098906,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}